Dose Optimization And Rare Diseases: Doing More With Less

 
• By Laura Helbling
  
The FDA said dose optimization may be more important for rare diseases because the small patient populations limit the number of possible clinical trials. (Shutterstock)

More from Clinical Trials

More from Rare Diseases